| Sep 3 |
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 30 |
Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial
|
| Aug 29 |
Gain slips after early-stage data for Parkinson’s therapy
|
| Aug 29 |
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
|
| Aug 8 |
Gain Therapeutics GAAP EPS of -$0.42
|
| Aug 8 |
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
|
| Aug 1 |
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
|
| Jul 9 |
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
|
| Jul 8 |
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
|
| Jul 1 |
Gain Therapeutics, Inc. (GANX) Special Call Transcript
|
